Groups
Company Size (Fulltime employees)
Partnering Objectives
Functionality
Headquartner in China
Biotech/Pharma Category
Biotech/Pharma Asset Stage
Medtech Category
Medtech Development Stage
Index
Countries
Reset

iX Biopharma Ltd Singapore

iX Biopharma is established in 2008, and listed on Singapore Stock Exchange (Catalist Board) in 2015. iX is a specialist in novel wafer formulations using patented sublingual delivery technology, WaferiXTM , which is patented in China to 2033. R&D and manufacturing at wholly-owned GMP licensed facility in Melbourne, Australia.
Website:
www.ixbiopharma.com
Company Size (Fulltime employees)
51-200
Year of foundation
2008
Partnering Objectives
Please specify your partnering goal
(1) Licensing Partner (2) Sublingual wafer development technology collaboration
Headquartner in China
No
Biotech/Pharma Category
Biotech/Pharma Asset Stage
Yuhuan Wang
Senior BD Manager 
Functionality
Business Development

Laurel Venture Capital China

focus on early-stage life science investment
Website:
www.laurelventure.com
Partnering Objectives
Headquartner in China
Yes
Biotech/Pharma Category
Winnie Liao
Legal Director 

leaguer group

创业投资 园区服务一体化
Website:
www.leaguer.com.cn
Partnering Objectives
Headquartner in China
Yes
Biotech/Pharma Category
laurent 高
specialist 

MedSci Healthcare United States

MedSci Healthcare was established in 2002 with the creation of Bioon.com, with headquarters in Shanghai and internationally in the U.S. We are committed to be the bridge between China and the U.S. healthcare. This is done by connecting Chinese healthcare professionals (HCPs) with U.S. resources and vice versa.
The company has done projects with major companies such as: Pfizer, Harvard Medical School, AstraZeneca, GSK, Abbott, Johnson & Johnson, Takeda, Novartis, Medtronic and many more. We have also worked with organizations such as the China Cardiovascular Association (CCA), Chinese Medical Doctor Association (CMDA) and more.
MedSci is a digital academic platform, scientific publishing support and multichannel marketing (MCM) organization. We use the term Academic Promotion Organization (APO). We use scientific writers, doctors & researcher scientists and commercialization experts to develop customized strategy & implementation to reach each organization’s goals.
Website:
medsci.cn
Company Size (Fulltime employees)
201-500
Partnering Objectives
Please specify your partnering goal
Looking for mutually beneficial partnerships and clients.
Headquartner in China
No
Biotech/Pharma Category
Chad Gloetzner
VP of Sales and Operations 
Functionality
Management

Mesa Verde Venture Partners United States

Life Sciences venture capital fund with three funds under management.
Website:
www.mesaverdevp.com
Company Size (Fulltime employees)
1-10
Year of foundation
2010
Partnering Objectives
Please specify your partnering goal
Meeting investors and potential companies
Headquartner in China
No
Biotech/Pharma Category
Assets Information 1
not applicable|||
Mr. Randy Berholtz
Senior Advisor 
Functionality
Management

Mira Life Science Ventures United States

Mira Life Science Ventures was established to change the paradigm for investment, incubation and development of new disruptive and game-changing technologies in the life sciences. Mira LSV will invest in medical devices, therapeutics, diagnostics, enabling technologies and digital healthcare. Mira LSV will focus its efforts in areas of significant unmet medical needs such as cancer, neurological diseases, infectious disease, autoimmune disease, inflammatory diseases, personalized medicine, cardiovascular disease and renal diseases.

In order to change the venture investment paradigm, Mira LSV was formed to break out of the traditional venture model and move to a more flexible, nimble and shareholder-centric model to accelerate development of these break-through products and technologies and bring them to patients. Mira LSV’s highly flexible business structure, broad and diverse access to deal-flow and highly experienced management team will ensure we have a significant positive impact on our healthcare system.

Website:
Mira Life Science Ventures
Company Size (Fulltime employees)
1-10
Year of foundation
2020
Partnering Objectives
Please specify your partnering goal
Seeking seed investments into Mira Life with global diversity
Headquartner in China
No
Biotech/Pharma Category
Medtech Category
Slides Deck
(pptx, 11.98MB)
Mr. Mel Rothberg
Chairman 
Functionality
Management

MSQ Ventures United States

MSQ Ventures is a New York-based cross-border advisory firm that bridges the healthcare industries globally by offering our deep knowledge, strong network, and local insights into the China market. We provide comprehensive advisory services for our clients’ cross-border projects: market assessment, in/out-licensing, joint ventures, and PR&IR. We currently have offices in New York (headquarter), Beijing, Shanghai, and Shenzhen.
Website:
http://msqventures.com/
Company Size (Fulltime employees)
1-10
Partnering Objectives
Please specify your partnering goal
in and out licensing
Headquartner in China
No
Biotech/Pharma Category
Mr. Estigarribia Marc
MD 

OncoMyx Therapeutics United States

OncoMyx Therapeutics is developing potentially best-in-class (multi-armed, IV/systemically-delivered, precision medicine) oncolytic immunotherapies based upon the myxoma virus (MYXV) platform, and we have demonstrated mechanism of action and combinatorial efficacy (tumor growth inhibition) when dosed IV with various checkpoint inhibitors in multiple animal models. Our company has the industry’s most experienced oncolytic virus (OV) development team and an experienced SAB, and CEO Steve Potts was previously an executive at Ignyta (acquired by Roche for $1.7B). OncoMyx raised a $25M series A in June 2019 to advance our lead preclinical program to IND, and among our investors are BIVF (exited OV investment ViraTx for $244M at preclinical stage in 2018) and Jonathan Lim (Ignyta CEO & current Erasca CEO). On the heels of presenting our preclinical data at SITC and announcing the appointment of Mirati CEO Chuck Baum as our new Chairperson, OncoMyx is seeking a $50M+ series B/crossover to prepare for an IPO and focus on a future transition into a clinical-stage organization. Pasted below are links to our SITC posters and some recent Fierce and BioSpace articles focused on our company.

https://www.oncomyx.com/oncomyx-announces-presentation-of-preclinical-efficacy-data-of-novel-oncolytic-immunotherapy-at-sitc-2020/
https://www.fiercebiotech.com/research/arming-rabbit-pox-virus-to-fight-cancer
https://www.biospace.com/article/oncomyx-s-oncolytic-virus-platform-shows-preclinical-efficacy-boosting-immunotherapy-potential/

Website:
https://www.oncomyx.com
Company Size (Fulltime employees)
11-50
Year of foundation
2018
Partnering Objectives
Please specify your partnering goal
Fundraising and Licensing-out
Headquartner in China
No
Biotech/Pharma Category
Biotech/Pharma Asset Stage
Slides Deck
(pdf, 2.38MB)
Dr. Steven Potts
Cofounder, CEO & Director 
Mr. Michael Wood
Cofounder, COO & CFO 
Functionality
Business Development
Dr. Leslie Sharp
Chief Scientific Officer 
Functionality
Research and Development

Product Creation Studio United States

PCS provides new product engineering and design services for medical device and Medtech companies. We have served enterprise and entrepreneurs for over two decades and our QMS is ISO13485:2016 certified.
Website:
www.productcreationstudio.com
Company Size (Fulltime employees)
11-50
Year of foundation
21
Partnering Objectives
Please specify your partnering goal
Provide high-end medical device design capabilities to Chinese healthcare companies.
Headquartner in China
No
Biotech/Pharma Category
Medtech Category
Target client type
Companies in need of custom medical devices, drug delivery solutions, diagnostics or research tools
Dr. Scott Thielman
CTO 
Functionality
Management

Rius Medical UG (Haftungsbeschränkt) Germany

About Rius Medical: Rius Medical is designing and developing a new generation of Commercial cell therapies positioned at the crossroads of two high-potential programs: (1.) genetically engineering red blood cells for an entirely new class of cellular medicines and (2.) potent NK-cell therapy products. Due to their mechanism of action, engineered red blood cells demonstrated treatments for wide range of patients from starving cancer cells to targeting autoimmune diseases. Building on exceptional progress in cell therapies, Rius Medical is in a unique position to offer Third-Generation red blood cells for drug delivery that addresses Rare Diseases, Oncology and Autoimmune Diseases like type 1 diabetes! Furthermore, harnessing the unique power of natural killer (NK) cells enables the treatment of cancer and infectious diseases such as Influenza virus or SARS-Coronavirus (i.e. COVID-19 pandemic). That’s right, NK-cells as vaccine delivery NOT for antibodies but for “memory T cells” activation!
Website:
https://ec.europa.eu/eipp/desktop/en/projects/project-11851.html
Company Size (Fulltime employees)
1-10
Year of foundation
2016
Partnering Objectives
Please specify your partnering goal
Partnering goal is to improve life and generate substantial economic return
Headquartner in China
No
Biotech/Pharma Category
Mr. Denis Demarais
Founder and CEO 
Functionality
Investment